The estimated Net Worth of Jerome B Zeldis is at least $1.44 Million dollars as of 22 May 2024. Jerome Zeldis owns over 20,000 units of PTC Therapeutics Inc stock worth over $1,113,315 and over the last 13 years he sold PTCT stock worth over $0. In addition, he makes $329,355 as Independent Director at PTC Therapeutics Inc.
Jerome has made over 16 trades of the PTC Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of PTCT stock worth $528,400 on 22 May 2024.
The largest trade he's ever made was buying 400,000 units of PTC Therapeutics Inc stock on 27 February 2017 worth over $200,000. On average, Jerome trades about 11,113 units every 78 days since 2011. As of 22 May 2024 he still owns at least 34,500 units of PTC Therapeutics Inc stock.
You can see the complete history of Jerome Zeldis stock trades at the bottom of the page.
Dr. Jerome B. Zeldis M.D. Ph.D. serves as Independent Director of the Company. Dr. Zeldis currently serves as the Chief Medical Officer of Sorrento Therapeutics, Inc., a public clinical-stage biopharmaceutical company. From August 2017 through September 2018, Dr. Zeldis served as the Chief Medical Officer of Celularity, Inc., a biotechnology company. Prior to joining Sorrento in August 2016, Dr. Zeldis served as Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation, a public biopharmaceutical company, where he had been employed since 1997. He previously served as Celgene's Senior Vice President of Clinical Research and Medical Affairs. Previously, Dr. Zeldis served as Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received an A.B. and M.S. from Brown University and a M.Phil., M.D. and Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry) from Yale University. Dr. Zeldis serves on the board of directors of several public companies, including, since 2011, Soligenix, Inc., a biopharmaceutical company listed on Nasdaq in December 2016; and, since 2016, MetaStat, Inc., a molecular diagnostic company traded on the OTCQB, and has previously served on the board of directors of several public companies including; Alliqua BioMedical, Inc., a Nasdaq-listed biomedical company, from 2011 to 2017; BioSig Technologies, Inc., a medical device company traded on the OTCQB, from 2015 to 2017; and Kalytera Therapeutics, Inc., a pharmaceutical company traded on the TSXV, from 2015 to 2017.
As the Independent Director of PTC Therapeutics Inc, the total compensation of Jerome Zeldis at PTC Therapeutics Inc is $329,355. There are 14 executives at PTC Therapeutics Inc getting paid more, with Stuart Peltz having the highest compensation of $7,759,440.
Jerome Zeldis is 70, he's been the Independent Director of PTC Therapeutics Inc since 2012. There are 3 older and 16 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.
Jerome's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059.
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel, and Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
PTC Therapeutics Inc executives and other stock owners filed with the SEC include: